Endra Life Sciences Inc. · NASDAQ:NDRA
Endra Life Sciences — Investor Presentation (December 2019)
14 slides from Endra Life Sciences's investor presentation, Dec 19, 2019
Slide 1: ENDRA Life Sciences: Addressing the Need in NAFLD Diagnosis
DECEMBER 2019 ENDRA Life Sciences: Addressing the Need In NAFLD Diagnosis INVESTOR PRESENTATION NASDAQ: NDRA
Slide 2: Safe Harbor
Safe Harbor Certain statements made in this presentation are forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial positi
Slide 3: ENDRA Snapshot
ENDRA Snapshot ©@e Enhanced tissue imaging Initial focus on Strong technology Leadership, advisors, & platform with $18 billion NAFLD & NASH, position with 64 IP —_ partners from GE opportunity to expand affecting 1B people? —assets® Healthcare, Stanford, clinical utility of 365,000" addressable ult
Slide 4: Why Measure Liver Fat in NAFLD-NASH?
Why Measure Liver Fat in NAFLD-NASH? TOTAL ANNUAL DIRECT MEDICAL COSTS IN U.S. FOR NAFLD: ~$103B! NAFLD: Asymptomatic, chronic condition with elevated fat build-up in the liver NASH: NAFLD with inflammation. Can lead to scarring, cirrhosis and cancer @E NDR LIFE SCIENCES 1* billion people affected®
Slide 5: Pipeline of New Therapeutics Advancing Rapidly
Pipeline of New Therapeutics Advancing Rapidly INCREASING THE NEED FOR CLINICIANS TO IDENTIFY & MONITOR PATIENTS ~ 50 NAFLD-NASH compounds in development’ 34 in Phase Il - Ill clinical trials’ ~ 4 expected to be commercially available within 2 years! ~ 50% of compounds’ target fat metabolism, enhanc
Slide 6: Diagnosing NAFLD Patients
Diagnosing NAFLD Patients CURRENTLY NO PRACTICAL, RIGOROUS TOOL FOR STAGING THE DISEASE Our Goal: An accessible, safe, high-value diagnostic tool Low ACCESS / AFFORDABILITY HIGH @MENDRA NASDAQ: NDRA 6
Slide 7: Total Addressable Market for NAFLD-NASH Fat Measurement Tool
Total Addressable Market for NAFLD-NASH Fat Measurement Tool $1B OPPORTUNITY ... WITH UPSIDE 2019: Number of Facilities’ Performing +» Global clinical facilities currently doing abdominal- 20,000 AbdominalLiver Ultrasound Scans H liver ultrasound scans who could buy one unit of ENDRA's liver technol
Slide 8: Solution: Thermo Acoustic Enhanced UltraSound (TAEUS)
Solution: Thermo Acoustic Enhanced UltraSound (TAEUS™) ENHANCED ULTRASOUND: RF SIGNALS QUANTITATE LIVER FAT FRACTION () Locate Liver with Traditional Ultrasound. ® Pulse RF waves into target tissue w/ TAEUS. Traditional Ultrasound aa [Ultrasound TAEUS RF Waves _ ad ) fa Traditional Ultrasound ® TAEU
Slide 9: ENDRA Preparing for Commercialization in 2020
ENDRA Preparing for Commercialization in 2020 IN-STEP WITH INTRODUCTION OF FIRST NAFLD-NASH THERAPIES 2019 2020 a Feasibility Product Evaluations ¥ Secure ISO-13485 certification Obtain CE Mark certification Y Build pre-commercial awareness Y Surpass 60* IP assets’ in portfolio Y Complete first in-h
Slide 10: Ramping Up For Commercial Success
Ramping Up For Commercial Success DRIVING AWARENESS SINCE 2018 WITH KEY CLINICAL STAKEHOLDERS IMAGING EXPERTS LIVER EXPERTS METABOLISM & Radiology Gastro-Hepatology LIFESTYLE EXPERTS es ~ 100,000 global ~ 45,000 global Endocrinology CLINICAL CONFERENCES, SOCIAL MEDIA practitioners’ il ractitioners’
Slide 11: ENDRA Booths at Scientific Meetings
ENDRA Booths at Scientific Meetings BUILDING AWARENESS & CLINICAL RELATIONSHIPS SINCE 2018 | Gastro- 2018 | 2019) Europe; U.S.A Rad e e American Institute for Ultrasound in Medicine Vv EASL- International Liver Congress Vv e e e International Congress on Fatty Liver (ICFL) JV e e e EASL NAFLD Summit
Slide 12: ENDRA Partners
ENDRA Partners SUPPORTING ENDRA’S TECHNICAL, CLINICAL AND COMMERCIAL DEVELOPMENT GE Healthcare $20B GLOBAL ULTRASOUND MARKET LEADER 30% MARKET SHARE * Strategic partnership since 2016 supports product development and introductions to GE ultrasound customers * GE has option to negotiate 1 year sales
Slide 13: Leadership
Leadership 8 $ % &, Francois Michelon Michael Thornton Renaud Maloberti Amy Sitzler David Wells Chairman & CEO cTo cco VP Engineering CFO 20° years in med-tech 15* years med-tech 20° years in med-tech. 20 years in engineering Previously CFO for 3 GE Healthcare, Smith & Founder, Enhanced 12 years in
Slide 14: Contact Us
Contact Us ENDRA CONTACT David Wells Chief Financial Officer (734) 997-0464 investors@endrainc.com www.endrainc.com INVESTOR & PUBLIC RELATIONS — MacDougall Christi Waarich Senior Director (781) 235-3060 endra@macbiocom.com 14
ENDRA Life Sciences — Investor Presentation (December 2019) on 6ix